Natixis Advisors LLC Acquires 441 Shares of Glaukos Co. (NYSE:GKOS)

Natixis Advisors LLC grew its holdings in shares of Glaukos Co. (NYSE:GKOS) by 1.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,738 shares of the medical instruments supplier’s stock after acquiring an additional 441 shares during the period. Natixis Advisors LLC’s holdings in Glaukos were worth $4,917,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of GKOS. Values First Advisors Inc. purchased a new position in shares of Glaukos during the 3rd quarter valued at $25,000. GAMMA Investing LLC lifted its stake in shares of Glaukos by 68.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after buying an additional 486 shares in the last quarter. KBC Group NV lifted its stake in shares of Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after buying an additional 201 shares in the last quarter. Fifth Third Wealth Advisors LLC purchased a new position in shares of Glaukos during the 2nd quarter valued at $187,000. Finally, Procyon Advisors LLC purchased a new position in shares of Glaukos during the 3rd quarter valued at $210,000. Institutional investors own 99.04% of the company’s stock.

Glaukos Stock Performance

Shares of NYSE:GKOS opened at $144.00 on Friday. The company has a market capitalization of $7.94 billion, a price-to-earnings ratio of -47.86 and a beta of 1.02. Glaukos Co. has a 12 month low of $59.22 and a 12 month high of $146.09. The firm’s 50-day moving average is $132.05 and its 200 day moving average is $123.31. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20. The company had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The firm’s revenue was up 23.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.50) EPS. Research analysts predict that Glaukos Co. will post -1.96 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Stifel Nicolaus lifted their target price on shares of Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. StockNews.com upgraded shares of Glaukos from a “sell” rating to a “hold” rating in a research note on Monday, October 21st. Piper Sandler set a $140.00 price target on shares of Glaukos in a research note on Thursday, October 17th. JPMorgan Chase & Co. boosted their price target on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, Truist Financial boosted their price target on shares of Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $134.55.

Insiders Place Their Bets

In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the transaction, the director now directly owns 32,336 shares in the company, valued at $4,225,345.12. This represents a 8.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Joseph E. Gilliam sold 2,275 shares of the company’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the transaction, the chief operating officer now owns 102,169 shares in the company, valued at $14,198,425.93. This represents a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.40% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.